Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) announced its earnings results on Wednesday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01), Briefing.com reports. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same period last year, the firm earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX traded down $0.04 during mid-day trading on Thursday, hitting $6.93. The company had a trading volume of 5,264,598 shares, compared to its average volume of 5,665,648. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The business’s 50-day simple moving average is $6.59 and its 200-day simple moving average is $7.63. Recursion Pharmaceuticals has a 12 month low of $5.03 and a 12 month high of $15.74. The firm has a market cap of $1.95 billion, a P/E ratio of -4.30 and a beta of 0.81.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the sale, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now owns 7,077,560 shares of the company’s stock, valued at approximately $47,561,203.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 171,682 shares of company stock worth $1,107,868. Company insiders own 15.75% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on RXRX. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.